- Home
- AGIO vs KALU Comparison
AGIO vs KALU Comparison
Compare AGIO & KALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- KALU
- Stock Information
- Founded
- AGIO 2007
- KALU 1946
- Country
- AGIO United States
- KALU United States
- Employees
- AGIO N/A
- KALU N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- KALU Metal Fabrications
- Sector
- AGIO Health Care
- KALU Industrials
- Exchange
- AGIO Nasdaq
- KALU Nasdaq
- Market Cap
- AGIO 1.4B
- KALU 1.3B
- IPO Year
- AGIO 2013
- KALU 1991
- Fundamental
- Price
- AGIO $39.23
- KALU $88.68
- Analyst Decision
- AGIO Buy
- KALU Buy
- Analyst Count
- AGIO 6
- KALU 3
- Target Price
- AGIO $58.60
- KALU $69.00
- AVG Volume (30 Days)
- AGIO 615.0K
- KALU 137.0K
- Earning Date
- AGIO 07-31-2025
- KALU 07-23-2025
- Dividend Yield
- AGIO N/A
- KALU 3.49%
- EPS Growth
- AGIO N/A
- KALU 0.39
- EPS
- AGIO 11.45
- KALU 3.06
- Revenue
- AGIO $37,035,000.00
- KALU $3,063,900,000.00
- Revenue This Year
- AGIO $22.30
- KALU $11.04
- Revenue Next Year
- AGIO $219.19
- KALU $7.33
- P/E Ratio
- AGIO $3.39
- KALU $28.81
- Revenue Growth
- AGIO 25.96
- KALU 1.56
- 52 Week Low
- AGIO $23.42
- KALU $46.81
- 52 Week High
- AGIO $62.58
- KALU $100.07
- Technical
- Relative Strength Index (RSI)
- AGIO 70.51
- KALU 72.39
- Support Level
- AGIO $34.60
- KALU $82.71
- Resistance Level
- AGIO $40.06
- KALU $89.67
- Average True Range (ATR)
- AGIO 1.45
- KALU 2.34
- MACD
- AGIO 0.43
- KALU 0.60
- Stochastic Oscillator
- AGIO 88.98
- KALU 92.88
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.